Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 11/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9801701 | 0.83 | HRH3 (0.46) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL9935981 | 0.83 | HRH3 (0.46) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL13887674 | 0.83 | HRH3 (0.46) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL9935153 | 0.83 | HRH3 (0.46) | HRH3CCR2KCNH2DRD3DRD4 | |
| Bromide SCHEMBL19439574 | 0.82 | HRH3 (0.44) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL24859542 | 0.80 | PDK1 (0.49) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL12312340 | 0.80 | HRH3 (0.43) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL9936319 | 0.80 | HRH3 (0.43) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL22463771 | 0.80 | HRH3 (0.43) | HRH3CCR2KCNH2DRD3DRD4 | |
| SCHEMBL10181368 | 0.80 | PDK1 (0.49) | HRH3CCR2KCNH2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9328138-B2 | HCV NS3 protease inhibitors | MSD ITALIA S.R.L. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-10-02 | — | — | US | disclosed |
| EP-2780026-A2 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013074386-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296136-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | HRH3 4618/4885CCR2 1942/4885KCNH2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.